Parameter
| Biomarker | Aβ42/40 Ratio | Full name | Amyloid β 42/40 Ratio | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, Susceptibility |
| Disease | Alzheimer's Disease | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | CSF/Plasma (SIMOA, ELISA) | ||
| Pathobiological Mechanisms | Aβ42 aggregates into oligomers and plaques, leading to neurotoxicity; Aβ40 is relatively stable; a decreased ratio more reliably reflects Aβ pathology than a single indicator. | ||||
| Clinical Availability Status | Research validation/early clinical use: CSF testing has been incorporated into research standards; large-scale validation of plasma testing is ongoing. | ||||
| Notes and Dynamics | Plasma Aβ42/40 is a current hotspot for early screening and population screening, with promising clinical application prospects. | ||||